Ansbert Gadicke - Nov 26, 2021 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role
10%+ Owner
Signature
/s/ Ansbert Gadicke
Stock symbol
ITOS
Transactions as of
Nov 26, 2021
Transactions value $
-$1,356,825
Form type
4
Date filed
11/30/2021, 03:49 PM
Previous filing
Nov 24, 2021
Next filing
Dec 2, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITOS Common Stock Sale -$389K -11K -0.22% $35.49 4.98M Nov 26, 2021 See Footnote F1, F2, F3, F4, F5
transaction ITOS Common Stock Sale -$370K -10.3K -0.21% $36.03 4.97M Nov 26, 2021 See Footnote F1, F6, F7, F8
transaction ITOS Common Stock Sale -$581K -16.9K -0.34% $34.46 4.95M Nov 29, 2021 See Footnote F1, F9, F10, F11
transaction ITOS Common Stock Sale -$17.7K -500 -0.01% $35.37 4.95M Nov 29, 2021 See Footnote F1, F12, F13, F14
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction effected pursuant to a plan established pursuant to Rule 10b5-1.
F2 The shares were sold as follows: 3,899 by MPM BioVentures 2014, L.P. ("BV 2014"), 134 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 2,463 by MPM BioVentures 2018, L.P. ("BV 2018"), 49 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 4,407 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC.
F3 BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.915 to $35.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The shares are held as follows: 1,721,258 by BV 2014, 97,289 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 59,245 by AM BV2014, 1,087,109 by BV 2018, 48,966 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 21,453 by AM BV2018 and 1,945,654 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
F6 The shares were sold as follows: 3,652 by BV 2014, 126 by AM BV2014, 2,306 by BV 2018, 45 by AM BV2018 and 4,129 by UBS Oncology.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.92 to $36.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 The shares are held as follows: 1,717,606 by BV 2014, 97,289 by BV 2014(B), 59,119 by AM BV2014, 1,084,803 by BV 2018, 48,966 by BV 2018(B), 21,408 by AM BV2018 and 1,941,525 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
F9 The shares were sold as follows: 6,001 by BV 2014, 207 by AM BV2014, 3,790 by BV 2018, 75 by AM BV2018 and 6,783 by UBS Oncology.
F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.06 to $34.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F11 The shares are held as follows: 1,711,605 by BV 2014, 97,289 by BV 2014(B), 58,912 by AM BV2014, 1,081,013 by BV 2018, 48,966 by BV 2018(B), 21,333 by AM BV2018 and 1,934,742 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
F12 The shares were sold as follows: 178 by BV 2014, 6 by AM BV2014, 112 by BV 2018, 2 by AM BV2018 and 202 by UBS Oncology.
F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.125 to $35.67 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F14 The shares are held as follows: 1,711,427 by BV 2014, 97,289 by BV 2014(B), 58,906 by AM BV2014, 1,080,901 by BV 2018, 48,966 by BV 2018(B), 21,331 by AM BV2018 and 1,934,540 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.